News

Research Teams Report on 18 Months of Progress from MS Societies’ Initial Studies on CCSVI and MS

Jan 27, 2012
Reports from 7 multi-disciplinary teams investigating CCSVI in MS indicate that they are making good progress toward providing essential data and critical analysis as these two-year projects move toward their completion. The studies were launched on July 1, 2010 with a more than $ 2.4 million commitment from the MS Society of Canada and the National MS Society (USA).

FDA Updates Tysabri Label to Include Lab Test that Helps Identify Person’s Risk of Developing PML

Jan 23, 2012
The U.S. FDA has approved a change to the prescription label for Tysabri to show that a lab test that detects antibodies to the JC virus can help determine a person’s risk of developing PML, a severe brain infection. PML has emerged in some people who have taken Tysabri. The lab test should enhance the ability to weigh risks and benefits of this therapy.

European Medicines Agency Commences Safety Review of Gilenya

Jan 20, 2012
The European Medicines Agency has started a review of the oral medication Gilenya (fingolimod, Novartis) after reports issued on January 20 that there have been 11 deaths among patients who received treatment. Our sympathies go out to the families of all of these individuals. As more information becomes available, we will release it as soon as possible to the MS community.

Sam’s Club Fundraiser to Benefit Society

Jan 17, 2012
Sam’s Club is enlisting the efforts of employees across the US to raise critical funds to benefit people affected by MS.

Fast Forward and Lineagen to Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis

Dec 16, 2011
Funding to Lineagen will Support Clinical Program in Collaboration with the University of Utah to Develop and Validate a Broad Array of Diagnostic and Prognostic Strategic Tools